HIV-1 Env DNA vaccine plus protein boost delivered by EP expands B- and T-cell responses and neutralizing phenotype in vivo.

We hereby demonstrate that immunization with the HIVBr27 vaccine encoding multiple conserved and promiscuous HIV-1 M- group consensus peptides is able to elicit broad, cross-clade

An equally enhanced T cell response was observed upon immunization with the V3 CTL epitope of the envelope (env) protein of the HIV-1 virus, expressed by reFlu, followed by a

Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T- cell responses

ing LigBrep as antigen and Alhydrogel as adjuvant, and determined the efficacy of these vaccination strategies in eliciting an IgG antibody response and in affording protective

Neutralizing antibody titres (geometric mean titres in each group) after immunization with an inactivated BoHV-1 265gE- vaccine, challenge with wild type virus (SV265 wt) and

Indeed, the presence of cross reactive T cell immunity is associated with protection in humans [11–13] and animals studies in which NP is delivered either as a recombinant protein

Absorbance in optical density (492 nm) for foals delivered by mares vaccinated with rEMA-2 of Theileria equi vaccine (n=9) and for foals delivered by control mares (n=9)

Currently, several candidates for an EV-A71 vaccine exist, including a formalin-inactivated whole virus vaccine, DNA vaccines, VLP and recombinant protein vaccines..